B-Cell Lymphomas
Information about B-cell lymphomas and CAR-T cell therapy assessment
The information on this page is for general informational purposes. Whether CAR-T therapy is suitable for a specific patient is determined only through specialist physician evaluation. This page does not constitute medical advice.
What is B-cell lymphoma?
Lymphoma is the general name for cancers that originate from the lymphatic system, which is part of the immune system. Lymph nodes, spleen, bone marrow and blood are associated with the lymphatic system. B-cell lymphomas develop from B lymphocytes, which play a role in antibody production in the immune system.
The course and treatment approach of B-cell lymphomas varies according to the subtype of the disease. Some lymphomas progress more slowly, while others may progress more rapidly. Therefore, not only the "lymphoma" diagnosis but also the subtype specified in the pathology report, the extent of the disease, genetic/molecular characteristics and the patient's general condition are important in the evaluation.
What are the symptoms?
Lymphoma symptoms can vary from person to person. Since these symptoms can also be seen in other diseases, no single symptom alone leads to a diagnosis.
Painless lymph node swelling in the neck, armpit or groin
Unexplained fever
Night sweats
Unintended weight loss
Chronic fatigue or weakness
Itching
Feeling of pressure in the chest, abdomen or neck
Shortness of breath or cough due to location
When to seek medical attention: You should consult a physician for persistent, increasing or unexplained complaints. In case of emergency symptoms such as sudden shortness of breath, chest pain, altered consciousness or high fever, you should apply to the nearest emergency health service.
How is diagnosis and evaluation done?
Lymphoma diagnosis and classification is usually based on pathological examination of a tissue sample. Additional blood tests, imaging methods and bone marrow examination may be performed to create the treatment plan.
Pathology and immunohistochemistry reports
PET/CT or other imaging results
Blood tests and organ functions
Stage and spread of the disease
Previous treatments and response to these treatments
Patient's performance status and comorbidities
Treatment approach
Treatment in B-cell lymphomas is planned according to the subtype, stage and patient characteristics.
Treatment options may include chemotherapy, immunotherapy, targeted therapies, radiotherapy, stem cell transplantation and CAR-T cell therapy in selected patients. Each patient's treatment plan is not the same. The selection of a treatment is made by the specialist team, taking into account the expected benefits, possible risks, the disease's response to previous treatments and the patient's general health condition.
When can CAR-T cell therapy be evaluated?
CAR-T cell therapy may come to the agenda in some B-cell lymphoma subtypes when the disease recurs or when standard treatments do not provide adequate response. For this evaluation, not only the patient's diagnosis but also the entire treatment history and current clinical status must be reviewed.
What is the exact subtype of the lymphoma?
What treatments were applied and how did the disease respond to these treatments?
Is the disease active, how widespread is it?
Are the patient's organ functions and general condition suitable for the treatment process?
What are the alternative or complementary treatment options?
Important: CAR-T therapy is not suitable for every B-cell lymphoma patient. Eligibility and treatment plan are determined as a result of evaluation by the hematology/oncology specialist and a multidisciplinary team with CAR-T experience.
Documents for evaluation
For the preliminary eligibility evaluation, the following documents should be prepared if possible:
- Current epicrisis or physician summary
- Pathology reports from diagnosis and relapse periods, if any
- PET/CT, CT, MRI or other imaging reports
- Recent blood tests
- Dates of applied treatments and response information
- History of stem cell transplantation, radiotherapy or intensive care, if any
- Current list of medications used
Frequently Asked Questions
Treatment results vary from patient to patient. No guarantee of result or cure can be given for CAR-T cell therapy. Possible individual benefits, risks and alternatives should be discussed with the specialist team.
No. The application is only the first step for medical documents to be reviewed by the specialist team for eligibility.
The timing of ongoing treatments and the clinical status of the disease are important. Evaluation can be made based on documents in coordination with the current hematology/oncology team.
Request an eligibility evaluation
Your medical documents are reviewed by our specialist team. Your application does not constitute a commitment to treatment; individual and multidisciplinary evaluation is required for each patient.